DLL3-Targeted Therapies
Jan 02, 2026
Is DLL3 Unlocking the New Code for the Neuroendocrine Cancers (NECs) Therapeutics’ Era?
Delta-like Ligand 3 (DLL3) is rapidly establishing a position as one of the promising targets in the treatment of aggressive Neuroendocrine Cancers (NECs), including Small Cell Lung Cancer (SCLC), Neuroendocrine Prostate Cancer (NEPC), and Large-Cell Neuroendocrine Carcinoma (LCNEC), where existing treatments deliv...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
